Sandra P D'Angelo

Sandra P D'Angelo

Memorial Sloan Kettering Cancer Center - Indore / United States
Others
AD Scientific Index ID: 4441125
person_outline Sandra P D'Angelo's MOST POPULAR ARTICLES
1-) Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...Nature genetics 51 (2), 202-206, 201929042019
2-) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialJS Weber, SP D\\\'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...The lancet oncology 16 (4), 375-384, 201528892015
3-) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialHL Kaufman, J Russell, O Hamid, S Bhatia, P Terheyden, SP D\\\'Angelo, ...The lancet oncology 17 (10), 1374-1385, 201611222016
4-) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialHA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ...The Lancet Oncology 18 (11), 1493-1501, 201712082017
5-) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at …TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ...Journal of Clinical Oncology 33 (28), 3193-3198, 201511192015